

ASX Announcement

March 2023 Quarterly Activity Report and Appendix 4C

- Human ethics approval received for observational stage of planned interventional Phase 1/2b cardioprotection clinical program using Zantrene®
- Two Contract Research Organisations (CROs) appointed to support the Zantrene breast cancer cardioprotection clinical program
- Collaborative research project started with Dr Brian Jensen of the University of North Carolina at Chapel Hill (USA) to explore how Zantrene protects the heart
- Dr Daniel Tillett stepped down from his roles of Executive Director and Chief Scientific Officer, Dr Tim Hammond appointed interim CSO
- Post quarter: market research conducted by third party research firm Triangle Insights shared on the potential market for Zantrene as an anticancer and cardioprotection treatment
- Mary Harney appointed Race Chair, taking over from Dr John Cullity who will remain on Board as Non-Executive Director

28 April 2023 – Race Oncology (ASX: RAC) is pleased to release its Q3 FY22 quarterly report and a business update. As of 31 March 2022, Race's cash, cash equivalents and investments totalled \$24.99m.

Race CEO Damian Clarke-Bruce said: *"The March quarter was significant for Race. We formally commenced the process of engaging with global key opinion leaders around Zantrene, with valuable early feedback. We also reported third party market data which characterised what the potential opportunity, if successful, could look like for Zantrene under the cardioprotection and anticancer scenarios.*

We now move toward a planned strategic collaborative meeting with key opinion leaders in the last days of April, as we look to continue the team's significant momentum. We are encouraged by the development of our new formulation, RC220 and our scientific results. With collaboration from our experienced scientific agency, Adnovate and our new team of clinical advisors, we are actively moving to further define our Target Product Profiles for Zantrene and to facilitate a clinical advisory board by June, enabling prioritisation of our resources and leading to enhancement of our Clinical Development Plans (CDP) by July/August. We will then be well positioned to execute on strategic commercialisation priorities for 2023 and beyond."

Race Interim CSO Tim Hammond said: *"After having been involved with Race for several months as part of Adnovate Clinical, I am delighted to have joined the Race team as Interim CSO through the quarter, to continue the work of Dr Daniel Tillett. I have had the opportunity to get to know the preclinical program and now starting to investigate how to further strategically align preclinical data support clinical opportunity for Race."*

Race Non-Executive Chair, Mary Harney said: *“Several important changes occurred at Board level through the period, with Dr Daniel Tillett stepping down as Executive Director (and CSO), I was honoured to be appointed Chair to succeed Dr John Cullity, who will stay on the Board as a Non-Executive Director. I would like to reiterate the Board’s thanks to Daniel for his very significant contribution to Race and also to thank John for his many years as Chair.”*

Recent clinical updates and upcoming milestones

Race is pleased to provide an update on several of the clinical and preclinical milestones noted in the Q2 FY22 quarterly report as expected in H1 FY22.

Clinical programs update

- **RI-002** Phase 2 trial in patients with Relapsed / Refractory AML (Investigator Sponsored Study in Israel): The Simon 2 stage design study has progressed to the Phase 2 efficacy (expansion) stage. Three patients have completed treatment in the Phase 2 stage. Results will be reported after 9 patients have completed treatment.
- **RAC-006** Phase 1/2 trial in patients with Extramedullary Acute Myeloid Leukemia (EMD AML) or Myelodysplastic Syndrome: seven AML patients have been pre-screened using ¹⁸F-FDG PET/CT for the presence of EMD AML tumours. Although one AML patient was identified as having EMD, they were not enrolled due to the advanced stage of their disease. The trial remains challenging to recruit and Race is working with investigators to explore the path forward.
- **RAC-008** Observational trial (Breast cancer patients receiving doxorubicin and cyclophosphamide (AC) therapy): human ethics approval from the Hunter New England Human Research Ethics Committee (NSW, Australia) for the study and for the conduct of the study at first site, Calvary Mater Newcastle, was received 31 January 2023 (ASX announcement: 1 February 2023). Approval for an additional site at Lake Macquarie Private Hospital, Gateshead (NSW, Australia), was received on 10 March 2023. Institutional governance approvals for each site are ongoing.

Preclinical programs update

Formulation

- Race continues ongoing development of RC220. The CMC team is actively pursuing an engineering and GMP formulation, designed for patients requiring I.V administration. This is an innovative and commercially critical program to support our cardio protection ambitions and programs still being explored like FTO & M6A.

Cardioprotection program

- Race initiated a study with Dr Brian Jensen (University of North Carolina, USA) to study the molecular mechanisms that underpin Zantrene’s cardioprotective properties (ASX announcement: 3 March 2023).

For personal use only

- US company Topogen was contracted to investigate Zantrene's cardioprotection mechanism of action (MOA).
- A second study was completed with CL Lab (USA) exploring Zantrene's ability to protect mouse hearts from doxorubicin-induced cardiotoxicity. The study confirmed the cardioprotective effects of Zantrene on heart function are dose-dependent. This essential understanding helps to define characteristics of Zantrene use in humans.

Therapeutic synergy and dosing

- A study was completed at the University of Newcastle (A/Prof Nikki Verrills) evaluating the cell-killing effects of the doxorubicin/cyclophosphamide/Zantrene 3-drug combination in breast cancer cell lines. The study supports the addition and potential synergy of Zantrene in AC therapy (anthracycline plus cyclophosphamide) used to treat breast cancer.

Clear cell renal cell carcinoma (kidney cancer)

- A scoping study was completed with Hera Biolabs (KY, USA) to evaluate the efficacy of Zantrene alone and in combination with cabozantinib (standard of care kinase inhibitor used to treat kidney cancer) in a rat model of clear cell renal cell carcinoma. While an encouraging trend towards Zantrene efficacy was seen both alone and in combination with cabozantinib, no statistically significant difference to control was found due to a large variation in tumour growth rate in this tumour model and the small number of animals of the study. Further work in a more consistent animal model is being considered to be initiated when the new RC220 formulation is available.

Multiple myeloma and cardioprotection

- Completed a study at Labcorp (USA) that enabled selection of a suitable multiple myeloma cell line (MM.1S) for use in a mouse model of MM.
- Completed a mouse tolerability study with Zantrene alone and in combination with the standard of care multiple myeloma drug, carfilzomib to identify a suitable dosing protocol for use in a mouse efficacy model.
- Completed a mouse efficacy model of multiple myeloma. Efficacy was demonstrated for Zantrene both alone and in combination with carfilzomib.

A novel in vivo model was explored to see if Zantrene can protect mouse hearts from the cardiotoxic effects of carfilzomib (CL Laboratory, USA). Due to the high toxicity of carfilzomib to mice, this model failed to produce significant cardiotoxic effects. Further work developing a suitable cardiotoxic model is continuing.

Acute Myeloid Leukaemia

- A human patient derived xenograft mouse model of AML was completed to explore the optimal combination of decitabine and Zantrene as a low toxicity treatment for AML (A/Prof Nikki Verrills, University of Newcastle). The Zantrene/decitabine

combination produced very strong AML suppressing effects and increased survival, relative to untreated controls.

Key events of the quarter

- On 1 February 2023, Race announced it had received human ethics approval from the Hunter New England Human Research Ethics Committee (NSW, Australia) for the observational stage of a planned Phase 1/2b clinical trial of Zantrene in breast cancer patients, to be treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors.
- On 2 March 2023, Race announced it had begun a new collaborative research project with the University of North Carolina at Chapel Hill (USA) to uncover at the molecular level how Zantrene protects the heart from chemotherapy. The program is being led by leading international cardio-oncologist Dr Brian Jensen of the McAllister Heart Institute.
- On 13 March 2023, Race announced it had appointed the Contract Research Organisations *Resolutum Global, Beyond Drug Development, and NSW Regional Biospecimen & Research Services*, to support the observational stage of a Phase 1/2b clinical trial of Zantrene in breast cancer patients treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors.
- On 24 March 2023, Race announced that Executive Director and CSO Dr Daniel Tillett had advised his decision to step down from his roles. Dr Tillett is providing ongoing support through June 2023 to ensure a smooth transition of his CSO responsibilities to the Race team, with oversight from Professor Tim Hammond, who will assume the role of Interim CSO.
- On 27 March 2023, Race announced that it had received \$1.48 million via the Research & Development (R&D) Tax Incentive from the Australian Taxation Office (ATO) for the financial year ended 30 June 2022 (FY22).

Other news from the quarter

- As part of the international engagement program, Race attended ACC.23 through 4-6 March 2023 in New Orleans. This annual meeting, hosted by the American College of Cardiology and the World Heart Federation, is a significant opportunity to meet clinicians and potential partners to discuss cardiooncology and the cardioprotective aspects of lead drug candidate, Zantrene.
- On 23 February 2023, University of Newcastle's Prof. Doan Ngo won the 2022 Australian Cardiovascular Alliance's "Game Changer Award" for her role in identifying that Zantrene can protect the heart from the cardiotoxic effects of cancer therapies. Prof. Ngo has also been a key driver in establishing Australia's first clinical cardio-oncology service that has served over 1,500 patients in the last 4 years, leading to

measurable improvements in patient outcomes and quality of life. Race congratulates Prof. Ngo for this well-deserved recognition.

- Following the General Meeting of Shareholders on 21 February 2023 where all resolutions were passed on a poll, Options were issued to Directors, Danny Sharp, Mary Harney and Damian Clarke-Bruce as summarised in two 3Y announcements issued to ASX on 3 March 2023.

Recent corporate updates

Post quarter, Race reported the following:

- Race released a short form, then complete commercial assessment (ASX Announcements: 4 April 2023 and 14 April 2023) of the market potential for Zantrene as a cardio-protective agent or dual cardio-protective + anti-cancer agent in breast, endometrial and ovarian cancers.

The research, which was conducted by Triangle Insights suggests a use case for Zantrene in nearly the entire identified target patient population as a cardio-protective oncology drug if anticancer benefits are demonstrated. A video was also available with the complete report, which can be accessed via the Race website at <https://raceoncology.com/april-2023-update>.

- On 20 April 2024, Race announced that Mary Harney had been appointed Non-Executive Chair, following more than two years as Race Non-Executive Director. Ms Harney succeeds Dr John Cullity, who will remain on the Board as Non-Executive Director and will continue to play an important role in commercialisation and deal development, while maintaining his ongoing position as a major shareholder.
- As Race builds international external expert engagement, we have now built a compelling list of experienced consultants helping to guide commercial targets and clinical development plans. The group, accessed via consulting agreements as needed, provides up to date, real world insights into patient needs, therapeutic options and the competitive landscape within this emerging area of science. Engaged consultants include:
 - Prof Aaron Sverdlov, Cardiologist and Clinical Scientist, University of Newcastle, NSW
 - Dr Susan Dent, Professor of Medicine, Medical Oncologist, Co-director Duke Cardio oncology program, Associate Director of Breast Cancer Research, Duke University Durham NC
 - Dr Chau T Dang, Medical Oncologist (Breast Cancer), Memorial Sloan Kettering Cancer Centre, New York
 - Dr Brian Jensen, Associate professor of medicine and cardio-oncologist at the University of North Carolina School of Medicine.

- Dr Amit Mehta, Medical Hematologist & Oncologist, Premier Haematology, university of Pennsylvania, North Carolina.
- Dr Joshua Mitchell, Assistant Professor of Medicine at John T. Milliken Department of Medicine Cardiovascular Division, Director Cardio-Oncology Centre of Excellence. Washington University, School of Medicine in St Louis.
- Dr Heather Moore (PHD) Clinical Pharmacist (Breast cancer) at Duke Cancer Centre Breast Clinic-Durham NC
- Dr Rohit Moudgil, Staff Cardiologist-Oncologist at Cleveland Clinic, NASA consultant, Associate Program Director of Internal Medicine, Director of Consult Service. Dir. Cardiology Education
- Dr Tomas Neilan, Cardiologist: Associate Professor of Medicine at Harvard medical School, Director, Cardio-Oncology Program and Co-Director, Cardiac MR PET CT Program, Mass General Heart Centre, Boston.

Summary of cash flow and quarterly activity

As of 31 March 2023, Race held cash and equivalents of \$24.99 million, compared with \$26.37 million on 31 December 2022. The net change in cash reserves is principally from continued research expenditure and product manufacture for clinical trials of \$2.23 million.

Listing rule 4.7C.3

Payments during the quarter to Related Parties amounted to \$309, comprising payments of salaries and superannuation to Executive Directors of \$225k and Board fees and superannuation to Non-Executive Directors of \$84k.

Shareholders by holding range

Race is pleased to report that shareholders totalled 8,875 as of 31 March 2023, showing continued shareholder interest in Race's progress.

Holding Ranges	Holders	Total Units	% Issued Share Capital
above 0 up to and including 1,000	3,757	1,659,792	1.03%
above 1,000 up to and including 5,000	2,607	6,443,448	3.99%
above 5,000 up to and including 10,000	834	6,276,533	3.89%
above 10,000 up to and including 100,000	1,423	44,682,471	27.70%
above 100,000	254	102,249,159	63.39%
Totals	8,875	161,311,403	100.00%

For personal use only

Top 20 shareholders at 31 March 2023

Position	Holder Name	Holding	% IC
1	Dr Daniel Tillett	13,692,075	8.61%
2	Mr Phillip Richard Perry	6,107,694	3.84%
3	Mr Mark Phillip Juan	5,488,892	3.45%
4	Biosynergy Partners Pty Ltd	5,102,194	3.21%
5	The Trust Company (Australia) Limited <MOF A/C>	4,415,468	2.78%
6	BNP Paribas Nominees PTY LTD <IB AU NOMS RETAILCLIENT DRP>	2,251,718	1.42%
7	Craganorig Holdings LLC	2,000,000	1.26%
8	Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C>	1,650,000	1.04%
9	Mr Anthony James Robinson <The Peeko Family NO 86 A/C>	1,640,000	1.03%
10	Mr Sandor Helby	1,300,000	0.82%
11	Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C>	1,249,820	0.79%
12	Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C>	1,080,000	0.68%
13	Citicorp Nominees Pty Limited	1,069,836	0.67%
14	Biosynergy Partners Pty Ltd	1,000,000	0.63%
15	Mr Alan Giles Sauran	934,944	0.59%
16	Kasajumi Holdings Pty Ltd	818,000	0.51%
17	Mr Van Quy Do	804,556	0.51%
18	Mr Brian James Walker	777,777	0.49%
19	Adra Future Co Limited	752,401	0.47%
20	Surpion PTY LTD <M W Suhr & Co A/C>	725,000	0.46%
	Total	52,860,375	33.24%
	Total issued capital¹ - selected security class(es)	159,003,478	100.00%

¹Excludes 2,307,925 shares voluntarily escrowed for 12 months (ASX Announcement: 14 November 2022).

For personal use only

Expected news

In H1 CY 2023, shareholders can expect:

▪ **Clinical**

- Updates on the Phase 2 investigator sponsored single centre triple combination trial in relapsed/refractory (R/R) AML patients being run in Israel (RI-002)
- Update on Phase 1/2 EMD AML, including Myelodysplastic Syndrome trial (RAC-006)
- Updates on the multi-centre observational trial of breast cancer patients receiving doxorubicin and cyclophosphamide (AC), running in Australia (RAC-008)

▪ **Preclinical**

- Updates on the RC220 peripheral formulation manufacturing program.
- Update on production of GMP Active Pharmaceutical Ingredient (API) from partner CDMO, Laurus Labs.
- Update on the cardioprotection mechanism of action studies with Race's cardio-oncology collaborator Dr Brian Jensen at the University of North Carolina (USA)
- Update on in vitro safety pharmacology and toxicology studies in support of downstream regulatory submissions and partner discussions.
- Updates on studies exploring the potential utility of Zantrene as an anti-cancer agent across more than 100 cancer cell types.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.



The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Damian Clarke-Bruce, CEO/MD on behalf
of the Race Board of Directors
damian.clarke-bruce@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au

For personal use only

RACE ONCOLOGY LIMITED (RAC)

Appendix 4C**Quarterly cash flow report for entities
subject to Listing Rule 4.7B****Name of entity**

RACE ONCOLOGY LIMITED (RAC)

ABN

61 149 318 749

Quarter ended ("current quarter")

31 March 2023

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,693)	(5,116)
(b) product manufacturing and operating costs	(537)	(1,583)
(c) advertising and marketing	(133)	(267)
(d) leased assets	-	-
(e) staff costs	(197)	(644)
(f) administration and corporate costs	(433)	(1,418)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	159	325
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,476	1,476
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,358)	(7,227)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-

For personal use only

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (share buy-back)	-	(1,283)
3.10	Net cash from / (used in) financing activities	-	(1,283)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	26,372	33,541
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,358)	(7,227)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(1,283)
4.5	Effect of movement in exchange rates on cash held	(28)	(45)
4.6	Cash and cash equivalents at end of period	24,986	24,986

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,086	2,372
5.2	Call deposits	21,900	24,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	24,986	26,372

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	309
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Payment to related parties as disclosed in item 6.1 as follows:

- \$84,572 payments for non-executive director fees for the period;
- \$224,530 payments to executive directors for the period, including superannuation paid during the quarter.

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	N/A	

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,358)
8.2 Cash and cash equivalents at quarter end (item 4.6)	24,986
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	24,986
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	18.41
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 April 2023

Authorised by: The Board of Race Oncology Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.